TISSIUM™ invents the next generation of synthetic polymers for tissue reconstruction :
- BIOMORPHIC : Conforms to and integrates with surrounding tissue to enable natural healing
- PROGRAMMABLE : Modular polymer design can be adjusted to match tissue-specific requirements
TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.
Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.
We have developed a fully integrated innovation, design, commercialisation and manufacturing platform to support our internal programmes as well as co-development partnerships with leaders in the medtech industry.
Maria Pereira's intervention at Biomim'expo 2019:
The board Biomim'review :
Releases :
Les Echos / 20 NOV 2019 / Tissium raises €39 million for its programmable surgical polymers
BFM BUSINESS / 21 NOV 2019 / French start-up Tissium, which wants to repair human tissue, raises €39 million
SOFINNOVA / 20 NOV 2019 / TISSIUM Closes €39M Series B Funding Round
LABIOTECH / 20 NOV 2019 / 39M Series B to Fund Biopolymers for Surgery and Implants
Contact:
English (UK) 
Français